Hypereosinophilic Syndrome (HES)
4 clinical trials · Condition
◉ Watch Hypereosinophilic Syndrome (HES)
| Record | Firm | Date |
|---|---|---|
| MAP to Provide Access to Nilotinib, for Patients With HES (NCT04498871) | Novartis Pharmaceuticals |
Track Hypereosinophilic Syndrome (HES) automatically
Every clearance here is in the API, with alerts when new ones post.